Blog
GLP-1 News & Updates
FDA updates, drug pricing news, insurance coverage changes, and the latest clinical trial results for GLP-1 weight loss medications.
CMS Extends Medicare GLP-1 Bridge Through 2027 as Main Program Stalls
Medicare's temporary GLP-1 coverage program gets 18-month extension while the permanent BALANCE model faces uncertainty over insurer participation.
The DoseNovo Nordisk Launches Ozempic Pill in US with $149 Starting Price
Novo Nordisk's Ozempic pill launches May 4 with self-pay pricing starting at $149/month, offering the first oral diabetes option under the Ozempic brand.
The DoseFDA Proposes to Block Large-Scale GLP-1 Compounding in Major Access Shift
The FDA proposed removing semaglutide, tirzepatide, and liraglutide from its 503B bulks list, potentially ending large-scale compounding of affordable GLP-1 alternatives for good.
The DoseFDA Opens First Public Review of Revolutionary Fast-Track Drug Program
The FDA will hold its first public meeting on June 4 to review the Commissioner's National Priority Voucher program that has cut drug approval times from 10-12 months to just 1-2 months.
The DoseFDA Sends 30 Warning Letters to Telehealth Companies Over Misleading GLP-1 Claims
The FDA cracked down on telehealth companies making false claims about compounded GLP-1 alternatives, sending 30 warning letters in its biggest enforcement action yet.
The DoseTrump Admin Delays Medicare GLP-1 Coverage After Insurers Balk at Program
The BALANCE Model for Medicare GLP-1 coverage is indefinitely postponed after failing to meet 80% insurer participation threshold, though Bridge program extends through 2027.
The DoseFDA Plans July Meeting to Ease Peptide Restrictions After RFK Jr. Push
RFK Jr.'s peptide advocacy leads FDA to schedule July meetings on lifting Biden-era restrictions for compounding pharmacies, potentially opening new wellness treatment access.
The DoseNovo's Oral Semaglutide First to Show Promise for Kids with Type 2 Diabetes
Novo Nordisk's PIONEER TEENS trial shows oral semaglutide reduced blood sugar by 0.83% in kids aged 10-17, potentially becoming the first oral GLP-1 for pediatric diabetes.
The DoseNovo Nordisk Files First-Ever Dual GLP-1/Amylin Drug for FDA Review
CagriSema combines semaglutide with a novel amylin receptor agonist, achieving 23% weight loss in trials and representing the first dual-mechanism GLP-1 therapy to seek approval.
The DoseFDA Sets New 'Four Prescription' Limit for Compounded GLP-1 Drugs
New FDA guidance restricts compounding pharmacies to just four monthly prescriptions of compounded GLP-1 copies, tightening access to affordable alternatives.
The DoseGLP-1 Pioneers Propose Radical Shift: Drop GLP-1 Entirely for Weight Loss
Researchers behind today's GLP-1 obesity drugs suggest targeting GLP-1 may not be necessary, proposing GIP/glucagon dual agonist that could match weight loss with fewer side effects.
The DoseLilly's Foundayo Sees Modest Launch with Just 1,390 Prescriptions in Debut Week
Eli Lilly's new oral GLP-1 pill Foundayo recorded only 1,390 prescriptions in its first week, a surprisingly modest start that contrasts sharply with Novo's oral Wegovy success.